We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan
· Delayed Price · Currency is TWD 27.10
+0.10 (0.37%)
Apr 29, 2026, 1:17 PM CST
We Can Medicines Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Net Income | -73.21 | -47.18 | 14.8 | 100.05 | 38.79 | Upgrade
|
| Depreciation & Amortization | 318.45 | 306.87 | 274.49 | 252.03 | 212.89 | Upgrade
|
| Other Amortization | 2.25 | 2.21 | 1.69 | 1.52 | 0.87 | Upgrade
|
| Loss (Gain) From Sale of Assets | 7.08 | 0.14 | 2.77 | 7.2 | 1.85 | Upgrade
|
| Asset Writedown & Restructuring Costs | 3.8 | 4.4 | 2 | 3.68 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.47 | -0.37 | - | -0.11 | -0.19 | Upgrade
|
| Stock-Based Compensation | 1.29 | 5.07 | 9.98 | 4.11 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.3 | -0.12 | -2.4 | 3.94 | 0.1 | Upgrade
|
| Other Operating Activities | 22.21 | 18.93 | 22.92 | 39.92 | 14.38 | Upgrade
|
| Change in Accounts Receivable | -14.96 | 47.61 | -83.48 | -14.72 | -54.84 | Upgrade
|
| Change in Inventory | 4.92 | -74.06 | -86.76 | -106.48 | -54.09 | Upgrade
|
| Change in Accounts Payable | 4.91 | -30.94 | 27.28 | 77.89 | 150.23 | Upgrade
|
| Change in Unearned Revenue | 0.86 | 0.79 | -3.43 | -1.63 | -1.97 | Upgrade
|
| Change in Other Net Operating Assets | 2.52 | 26.94 | -40.03 | -20.84 | -1.04 | Upgrade
|
| Operating Cash Flow | 240.02 | 260.68 | 139.84 | 346.67 | 457.16 | Upgrade
|
| Operating Cash Flow Growth | -7.92% | 86.41% | -59.66% | -24.17% | 478.31% | Upgrade
|
| Capital Expenditures | -35.53 | -63.95 | -92.55 | -122.54 | -339.58 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.31 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.4 | -5.29 | -1.4 | -0.38 | -3.37 | Upgrade
|
| Other Investing Activities | 1.51 | -0.11 | -4.5 | -5.53 | -2.81 | Upgrade
|
| Investing Cash Flow | -34.42 | -69.04 | -98.45 | -128.45 | -345.76 | Upgrade
|
| Short-Term Debt Issued | 85 | 555 | 1,050 | 265 | 6 | Upgrade
|
| Long-Term Debt Issued | 10 | - | - | - | 150 | Upgrade
|
| Total Debt Issued | 95 | 555 | 1,050 | 265 | 156 | Upgrade
|
| Short-Term Debt Repaid | -85 | -690 | -915 | -265 | -6 | Upgrade
|
| Long-Term Debt Repaid | -252.56 | -238.09 | -211.89 | -188.45 | -164.98 | Upgrade
|
| Total Debt Repaid | -337.56 | -928.09 | -1,127 | -453.45 | -170.98 | Upgrade
|
| Net Debt Issued (Repaid) | -242.56 | -373.09 | -76.89 | -188.45 | -14.98 | Upgrade
|
| Issuance of Common Stock | 4.58 | 356.37 | - | - | - | Upgrade
|
| Common Dividends Paid | - | -12 | - | - | - | Upgrade
|
| Other Financing Activities | -27.94 | -17.78 | -20.23 | -16.88 | -13.23 | Upgrade
|
| Financing Cash Flow | -265.92 | -46.5 | -97.12 | -205.32 | -28.21 | Upgrade
|
| Net Cash Flow | -60.31 | 145.15 | -55.73 | 12.9 | 83.18 | Upgrade
|
| Free Cash Flow | 204.5 | 196.73 | 47.29 | 224.13 | 117.58 | Upgrade
|
| Free Cash Flow Growth | 3.95% | 316.03% | -78.90% | 90.63% | 458.55% | Upgrade
|
| Free Cash Flow Margin | 6.35% | 6.02% | 1.51% | 6.79% | 4.21% | Upgrade
|
| Free Cash Flow Per Share | 4.54 | 4.53 | 1.12 | 5.37 | 2.94 | Upgrade
|
| Cash Interest Paid | 25.61 | 27.43 | 23.45 | 19.06 | 14.37 | Upgrade
|
| Cash Income Tax Paid | 0.08 | 5.63 | 6.72 | - | - | Upgrade
|
| Levered Free Cash Flow | 229.38 | 156.69 | -2.81 | 141.92 | -72.62 | Upgrade
|
| Unlevered Free Cash Flow | 245.38 | 173.84 | 11.86 | 153.84 | -63.6 | Upgrade
|
| Change in Working Capital | -41.68 | -29.28 | -186.41 | -65.68 | 188.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.